BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28669690)

  • 1. The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ reinfusion in multiple myeloma.
    Martin RMG; Ricci MJ; Foley R; Mian HS
    Transfus Apher Sci; 2017 Aug; 56(4):552-557. PubMed ID: 28669690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma.
    Stiff PJ; Micallef I; Nademanee AP; Stadtmauer EA; Maziarz RT; Bolwell BJ; Bridger G; Marulkar S; Hsu FJ; DiPersio JF
    Biol Blood Marrow Transplant; 2011 Aug; 17(8):1146-53. PubMed ID: 21126595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CXCR4 expression on transplanted peripheral blood CD34+ cells: relationship to engraftment after autologous transplantation in a cohort of multiple myeloma patients.
    Hicks C; Isaacs A; Wong R; Chong BH
    Ann Hematol; 2011 May; 90(5):547-55. PubMed ID: 20957366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does Reinfusion of Stem Cell Products on Multiple Days Affect Engraftment?
    Solmaz Medeni Ş; Türkyılmaz D; Acar C; Sevindik ÖG; Yüksel F; Pişkin Ö; Özcan MA; Demirkan F; Ündar B; Alacacıoğlu İ; Özsan GH
    Turk J Haematol; 2018 Nov; 35(4):271-276. PubMed ID: 29923493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.
    Klaus J; Herrmann D; Breitkreutz I; Hegenbart U; Mazitschek U; Egerer G; Cremer FW; Lowenthal RM; Huesing J; Fruehauf S; Moehler T; Ho AD; Goldschmidt H
    Eur J Haematol; 2007 Jan; 78(1):21-8. PubMed ID: 17042762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors that predict delayed platelet recovery after autologous stem cell transplantation for lymphoma or myeloma.
    Nagayama T; Ashizawa M; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Fujiwara SI; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
    Ann Hematol; 2020 Dec; 99(12):2893-2901. PubMed ID: 32572522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
    Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer.
    Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS
    J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early and long-term engraftment after autologous peripheral stem cell transplantation in acute myeloid leukemia patients.
    Specchia G; Pastore D; Mestice A; Liso A; Carluccio P; Leo M; Casanova M; Sibilla S; Giannoccaro M; Liso V
    Acta Haematol; 2006; 116(4):229-37. PubMed ID: 17119322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human thrombopoietin improved platelet engraftment after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.
    Gu J; Liu J; Li X; Zou W; Huang B; Chen M; Li J
    Cancer Med; 2021 Nov; 10(21):7641-7649. PubMed ID: 34569193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
    Hicks C; Wong R; Manoharan A; Kwan YL
    Ann Hematol; 2007 Aug; 86(8):591-8. PubMed ID: 17492259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the CD34+ 38- cells in posttransplant hematopoietic recovery.
    Hénon P; Sovalat H; Bourderont D; Ojeda-Uribe M; Arkam Y; Wunder E; Raidot JP; Husseini F; Audhuy B
    Stem Cells; 1998; 16 Suppl 1():113-22. PubMed ID: 11012153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia.
    Gunn N; Damon L; Varosy P; Navarro W; Martin T; Ries C; Linker C
    Biol Blood Marrow Transplant; 2003 Oct; 9(10):643-8. PubMed ID: 14569560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ideal body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss.
    Maclean PS; Parker AN; McQuaker IG; Clark AD; Farrell E; Douglas KW
    Bone Marrow Transplant; 2007 Oct; 40(7):665-9. PubMed ID: 17646841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
    de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
    Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High CD34(+) cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation.
    Ketterer N; Salles G; Raba M; Espinouse D; Sonet A; Tremisi P; Dumontet C; Moullet I; Eljaafari-Corbin A; Neidhardt-Berard EM; Bouafia F; Coiffier B
    Blood; 1998 May; 91(9):3148-55. PubMed ID: 9558369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.
    Lee S; Kim S; Kim H; Baek EJ; Jin H; Kim J; Kim HO
    Vox Sang; 2008 Feb; 94(2):146-52. PubMed ID: 18028260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience.
    Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P
    Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation.
    Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE
    Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre infusion, post thaw CD34+ peripheral blood stem cell enumeration as a predictor of haematopoietic engraftment in autologous haematopoietic cell transplantation.
    D'Rozario J; Parisotto R; Stapleton J; Gidley A; Owen D
    Transfus Apher Sci; 2014 Jun; 50(3):443-50. PubMed ID: 24680293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.